KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -252.60% |
| Oct 31, 2024 | -9.92% |
| Jul 31, 2024 | -237.87% |
| Apr 30, 2024 | 201.05% |
| Jan 31, 2024 | -0.20% |
| Oct 31, 2023 | -2.84% |
| Jul 31, 2023 | 8.89% |
| Apr 30, 2023 | -17.96% |
| Jan 31, 2023 | -3.06% |
| Oct 31, 2022 | 2.45% |
| Jul 31, 2022 | 1.77% |
| Apr 30, 2022 | -0.45% |
| Jan 31, 2022 | -13.35% |
| Oct 31, 2021 | -21.16% |
| Jul 31, 2021 | -8.54% |
| Apr 30, 2021 | -41.60% |
| Jan 31, 2021 | 0.54% |
| Oct 31, 2020 | 11.25% |
| Jul 31, 2020 | -65.05% |
| Apr 30, 2020 | 30.42% |
| Jan 31, 2020 | -40.62% |
| Oct 31, 2019 | 2.12% |
| Jul 31, 2019 | 17.51% |
| Apr 30, 2019 | -83.24% |
| Jan 31, 2019 | -26.62% |
| Oct 31, 2018 | 32.24% |
| Jul 31, 2018 | -953.27% |
| Apr 30, 2018 | 87.45% |
| Jan 31, 2018 | -4.97% |
| Oct 31, 2017 | -1.18% |
| Jul 31, 2017 | -17.28% |
| Apr 30, 2017 | 46.51% |
| Jan 31, 2017 | -85.22% |
| Oct 31, 2016 | 5.23% |
| Mar 31, 2016 | -16.76% |
| Dec 31, 2015 | -13.30% |
| Sep 30, 2015 | 14.43% |
| Jun 30, 2015 | -12.54% |
| Sep 30, 2014 | -55.84% |
| Jun 30, 2014 | -24.96% |